ARENTFOX SCHIFF LLP for HEMATECH INC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Funding for development of medical therapeutics for bioterrorism response
Foreign entity interest: Kirin Pharma Company, Ltd., identified on the LD-1, is interested in the above-referenced lobbying activities that affect the commercial activities and overall business of its subsidiary Hematech, Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGO KLOSTERMAN | — |
| RACHEL G LATTIMORE | — |
| DAN RENBERG | — |
Budget/Appropriations BUD
S. 3001 (National Defense Authorization Act for Fiscal Year 2009), H.R. 2638 (Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009) regarding FY '09 Department of Defense appropriations (Division C), FY '09 Labor/HHS/Education appropriations and FY '10 Department of Defense budget, all regarding advanced therapeutic development for bioterrorism response
Foreign entity interest: Kirin Pharma Company, Ltd., identified on the LD-1, is interested in the above-referenced lobbying activities that affect the commercial activities and overall business of its subsidiary Hematech, Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGO KLOSTERMAN | — |
| RACHEL G LATTIMORE | — |
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.